Skip to main content
Top
Published in: Tumor Biology 10/2016

Open Access 01-10-2016 | Original Article

Cytosolic Ku70 regulates Bax-mediated cell death

Authors: Manila Hada, Chitra Subramanian, Phillip C. Andrews, Roland P. S. Kwok

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

The first known function of Ku70 is as a DNA repair factor in the nucleus. Using neuronal neuroblastoma cells as a model, we have established that cytosolic Ku70 binds to the pro-apoptotic protein Bax in the cytosol and blocks Bax’s cell death activity. Ku70-Bax binding is regulated by Ku70 acetylation in that when Ku70 is acetylated Bax dissociates from Ku70, triggering cell death. We propose that Ku70 may act as a survival factor in these cells such that Ku70 depletion triggers Bax-dependent cell death. Here, we addressed two fundamental questions about this model: (1) Does all Bax, which is a cytosolic protein, bind to all cytosolic Ku70? and (2) Is Ku70 a survival factor in cells types other than neuronal neuroblastoma cells? We show here that, in neuronal neuroblastoma cells, only a small fraction of Ku70 binds to a small fraction of Bax; most Bax is monomeric. Interestingly, there is no free or monomeric Ku70 in the cytosol; most cytosolic Ku70 is in complex with other factors forming several high molecular weight complexes. A fraction of cytosolic Ku70 also binds to cytosolic Ku80, Ku70’s binding partner in the nucleus. Ku70 may not be a survival factor in some cell types (Ku70-depletion less sensitive) because Ku70 depletion does not affect survival of these cells. These results indicate that, in addition to Ku70 acetylation, other factors may be involved in regulating Ku70-Bax binding in the Ku70-depletion less sensitive cells because Ku70 acetylation in these cells is not sufficient to dissociate Bax from Ku70 or to activate Bax.
Literature
1.
go back to reference Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–56.CrossRefPubMed Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–56.CrossRefPubMed
2.
go back to reference Doerflinger M, Glab JA, Puthalakath H. BH3-only proteins: a 20-year stock-take. FEBS J. 2015;282(6):1006–16.CrossRefPubMed Doerflinger M, Glab JA, Puthalakath H. BH3-only proteins: a 20-year stock-take. FEBS J. 2015;282(6):1006–16.CrossRefPubMed
3.
go back to reference Zhai D et al. Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak. J Biol Chem. 2005;280(16):15815–24.CrossRefPubMed Zhai D et al. Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak. J Biol Chem. 2005;280(16):15815–24.CrossRefPubMed
5.
go back to reference Sawada M et al. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol. 2003;5(4):320–9.CrossRefPubMed Sawada M et al. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol. 2003;5(4):320–9.CrossRefPubMed
7.
go back to reference Mimori T, Hardin JA, Steitz JA. Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem. 1986;261(5):2274–8.PubMed Mimori T, Hardin JA, Steitz JA. Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem. 1986;261(5):2274–8.PubMed
8.
go back to reference Featherstone C, Jackson SP. Ku, a DNA repair protein with multiple cellular functions? Mutat Res. 1999;434(1):3–15.CrossRefPubMed Featherstone C, Jackson SP. Ku, a DNA repair protein with multiple cellular functions? Mutat Res. 1999;434(1):3–15.CrossRefPubMed
9.
go back to reference Subramanian C et al. CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A. Neoplasia. 2007;9(6):495–503.CrossRefPubMedPubMedCentral Subramanian C et al. CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A. Neoplasia. 2007;9(6):495–503.CrossRefPubMedPubMedCentral
10.
go back to reference Cohen HY et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell. 2004;13(5):627–38.CrossRefPubMed Cohen HY et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell. 2004;13(5):627–38.CrossRefPubMed
12.
go back to reference Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ. 2014;21(2):196–205.CrossRefPubMed Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ. 2014;21(2):196–205.CrossRefPubMed
14.
15.
go back to reference Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.CrossRefPubMed Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.CrossRefPubMed
16.
go back to reference Clifford-Nunn B, Showalter HD, Andrews PC. Quaternary diamines as mass spectrometry cleavable crosslinkers for protein interactions. J Am Soc Mass Spectrom. 2012;23(2):201–12.CrossRefPubMed Clifford-Nunn B, Showalter HD, Andrews PC. Quaternary diamines as mass spectrometry cleavable crosslinkers for protein interactions. J Am Soc Mass Spectrom. 2012;23(2):201–12.CrossRefPubMed
17.
go back to reference Subramanian C et al. CREB-binding protein regulates Ku70 acetylation in response to ionization radiation in neuroblastoma. Mol Cancer Res. 2013;11(2):173–81.CrossRefPubMed Subramanian C et al. CREB-binding protein regulates Ku70 acetylation in response to ionization radiation in neuroblastoma. Mol Cancer Res. 2013;11(2):173–81.CrossRefPubMed
18.
go back to reference Deriano L, Roth DB. Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage. Annu Rev Genet. 2013;47:433–55.CrossRefPubMed Deriano L, Roth DB. Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage. Annu Rev Genet. 2013;47:433–55.CrossRefPubMed
19.
go back to reference Hsu YT, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem. 1998;273(17):10777–83.CrossRefPubMed Hsu YT, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem. 1998;273(17):10777–83.CrossRefPubMed
22.
go back to reference Westphal D et al. Molecular biology of Bax and Bak activation and action. Biochim Biophys Acta. 2011;1813(4):521–31.CrossRefPubMed Westphal D et al. Molecular biology of Bax and Bak activation and action. Biochim Biophys Acta. 2011;1813(4):521–31.CrossRefPubMed
23.
go back to reference Kerr E et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ. 2012;19(8):1317–27.CrossRefPubMedPubMedCentral Kerr E et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ. 2012;19(8):1317–27.CrossRefPubMedPubMedCentral
Metadata
Title
Cytosolic Ku70 regulates Bax-mediated cell death
Authors
Manila Hada
Chitra Subramanian
Phillip C. Andrews
Roland P. S. Kwok
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5202-z

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine